BridgeBio said Q4 FY2025 total revenues, net were USD 154.2 million, including net product revenue of USD 146.0 million, royalty revenue of USD 5.3 million and license and services revenue of USD 2.9 million. For FY2025, total revenues, net were USD 502.1 million, including net product revenue of USD 362.4 million, royalty revenue of USD 11.4 million and license and services revenue of USD 128.3 million. Q4 operating costs and expenses were USD 293.7 million, including R&D of USD 116.4 million and SG&A of USD 158.1 million, and the company posted a Q4 net loss attributable to common stockholders of USD 192.9 million, or USD 1.00 per share. For FY2025, operating costs and expenses were USD 1.0 billion, including R&D of USD 452.0 million and SG&A of USD 531.2 million, and net loss attributable to common stockholders was USD 724.9 million, or USD 3.78 per share. Cash, cash equivalents and marketable securities were USD 587.5 million at Dec. 31, 2025; BridgeBio also issued USD 632.5 million of convertible senior notes due 2033 in January 2026. On the business side, BridgeBio said its ATTR-CM drug Attruby (acoramidis) had 7,804 unique patient prescriptions written by 1,856 unique prescribers as of Feb. 20, 2026, and delivered 35% quarter-over-quarter growth in Q4 net product revenue. The company highlighted positive Phase 3 readouts for oral infigratinib in achondroplasia (PROPEL 3 met its primary endpoint; NDA planned in 2H 2026), BBP-418 in LGMD2I/R9 (positive interim Phase 3 FORTIFY results; FDA recommended pursuing traditional approval; NDA planned in 1H 2026) and encaleret in ADH1 (positive Phase 3 CALIBRATE results; pre-NDA interaction completed; NDA planned in 1H 2026). BridgeBio also cited the reauthorization of the Rare Pediatric Review Voucher program, under which BBP-418, BBP-812 and infigratinib may be eligible for a voucher upon approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602241601PRIMZONEFULLFEED9660369) on February 24, 2026, and is solely responsible for the information contained therein.